Phenocopies of sarcomere gene mediated hypertrophic cardiomyopathy in children

Ahluwalia, 2021, Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy, Heart, 107, 183, 10.1136/heartjnl-2020-316798 Lopez-Sainz, 2020, Clinical features and natural history of PRKAG2 variant cardiac glycogenosis, J Am Coll Cardiol, 76, 186, 10.1016/j.jacc.2020.05.029 Darden, 2021, Fasciculoventricular and atrioventricular accessory pathways in patients with Danon disease and preexcitation: a multicenter experience, Heart Rhythm, 18, 1194, 10.1016/j.hrthm.2021.03.024 Cenacchi, 2020, Review: danon disease: review of natural history and recent advances, Neuropathol Appl Neurobiol, 46, 303, 10.1111/nan.12587 Hopkin, 2016, The management and treatment of children with Fabry disease: a United States-based perspective, Mol Genet Metab, 117, 104, 10.1016/j.ymgme.2015.10.007 Sachdev, 2002, Prevalence of Anderson-fabry disease in male patients with late onset hypertrophic cardiomyopathy, Circulation, 105, 1407, 10.1161/01.CIR.0000012626.81324.38 Arends, 2017, Retrospective study of long-term outcomes of enzyme replacement therapy in fabry disease: analysis of prognostic factors, PLoS One, 12, 10.1371/journal.pone.0182379 Wilcox, 2008, Females with fabry disease frequently have major organ involvement: lessons from the fabry registry, Mol Genet Metab, 93, 112, 10.1016/j.ymgme.2007.09.013 Germain, 2019, Consensus recommendations for diagnosis, management and treatment of fabry disease in paediatric patients, Clin Genet, 96, 107, 10.1111/cge.13546 Peterschmitt, 2021, Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral Venglustat in healthy volunteers, Clin Pharmacol Drug Dev, 10, 86, 10.1002/cpdd.865 Khan, 2021, Lentivirus-mediated gene therapy for fabry disease, Nat Commun, 12, 1178, 10.1038/s41467-021-21371-5 Pagant, 2021, ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic alpha-Gal A activity and effective substrate reduction in Fabry mice, Mol Ther, 10.1016/j.ymthe.2021.03.018 Kohler, 2018, Pompe disease: from basic science to therapy, Neurotherapeutics, 15, 928, 10.1007/s13311-018-0655-y Salabarria, 2020, Advancements in AAV-mediated gene therapy for pompe disease, J Neuromuscul Dis, 7, 15, 10.3233/JND-190426 Chan, 2017, The emerging phenotype of late-onset pompe disease: a systematic literature review, Mol Genet Metab, 120, 163, 10.1016/j.ymgme.2016.12.004 Monda, 2021, Hypertrophic cardiomyopathy in children: pathophysiology, diagnosis, and treatment of non-sarcomeric causes, Front Pediatr, 9, 10.3389/fped.2021.632293 Aoki, 2016, Recent advances in RASopathies, J Hum Genet, 61, 33, 10.1038/jhg.2015.114 Gelb, 2015, Cardiomyopathies in Noonan syndrome and the other RASopathies, Prog Pediatr Cardiol, 39, 13, 10.1016/j.ppedcard.2015.01.002 Roberts, 2013, Noonan syndrome, Lancet, 381, 333, 10.1016/S0140-6736(12)61023-X Andelfinger, 2019, Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition, J Am Coll Cardiol, 73, 2237, 10.1016/j.jacc.2019.01.066 Hahn, 2015, Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog, Am J Med Genet A, 167A, 744, 10.1002/ajmg.a.36982 Brunel-Guitton, 2015, Mitochondrial diseases and cardiomyopathies, Can J Cardiol, 31, 1360, 10.1016/j.cjca.2015.08.017 Scaglia, 2004, Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease, Pediatrics, 114, 925, 10.1542/peds.2004-0718 Brambilla, 2020, Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders, Orphanet J Rare Dis, 15, 196, 10.1186/s13023-020-01466-w